I-Mab Biopharma Raises $104 Million in Nasdaq IPO

I-Mab Biopharma Raises $104 Million in Nasdaq IPO

Edward Kim | |

First Chinese biotech company to go public in the US since September 2017.

Yield Curve's Still Weird; Fed's Bullard Is Okay With That

Reuters | |

St. Louis Fed President James Bullard is ready to leave monetary policy on hold for 2020.

Socially Responsible Investing: Can the Ratings Be Trusted?

Guild Investment Management | |

Competing ESG scores show only minimal correlation.

The Muni Tide Keeps Rolling In | |

Investors poured $2.89 billion into muni funds last week, the highest total since 1992 and the 53rd straight week of inflows.

Dollar Weakness Could Be the Catalyst Commodities Are Seeking

Frank Holmes | |

The US Dollar Index displayed a specific bearish signal last week that we haven’t seen since May 2017.

Elon Musk Nears $346 Million Payday as Tesla Market Value Soars

Reuters | |

Tesla stock has more than doubled in the last three months.

The Increasing Wait for Promising Companies To Get Public

Dan Conner | |

Expect the trend of private companies staying private to continue.

Arcutis Biotherapeutics Files $100 Million IPO for Dermatological Pipeline

Edward Kim | |

The company is pursuing dermatological therapies, with its lead product candidate in Phase 3 clinical trials for plaque psoriasis.

What Does African Swine Fever Have To Do With the Trade Truce? | |

China’s promise to purchase more US agricultural products in 2020 is as much rooted in necessity as it is in goodwill.

Market MVP Award Goes To...

David Nelson, CFA CMT | |

Who was the MVP in an extraordinary year for the markets?

Blockchain in Healthcare - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Health - How Blockchain technology can make health care systems more patient-centric and sustainable


Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more